Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder.
Neuropsychopharmacology. 2013 Dec 6;
Authors: Madhoo M, Keefe RS, Roth RM, Sambunaris A, Wu J, Trivedi MH, Anderson CS, Lasser R
Abstract
Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antidepressant monotherapy for executive dysfunction in partially or fully remitted major depressive disorder (MDD). This randomized, placebo-controlled study (NCT00985725) enrolled 143 adults (18-55 y) with mild MDD (Montgomery-Åsberg Depression Rating Scale [MADRS] score 18) and executive dysfunction (Behavior Rating Inventory of Executive Function-Adult Version [BRIEF-A] Self-Report Global Executive Composite [GEC] T score 60) on stable antidepressant monotherapy for 8 weeks. After 2 weeks of screening, participants were randomized to 9 weeks of double-blind LDX (20-70 mg/d) or placebo augmentation, followed by 2 weeks of single-blind placebo. The primary endpoint was change from baseline to week 9/end of study (EOS) in BRIEF-A Self-Report GEC T score; secondary assessments included the BRIEF-A Informant Report, MADRS, and treatment-emergent adverse events (TEAEs). Of 143 randomized participants, 119 completed double-blind treatment (placebo, n=59; LDX, n=60). Mean±SD BRIEF-A GEC T scores decreased from baseline (placebo, 74.2±8.88; LDX, 76.8±9.66) to week 9/EOS (placebo, 61.4±14.61; LDX, 55.2±16.15); the LS mean (95% CI) treatment difference significantly favored LDX (-8.0 [-12.7, -3.3] P=0.0009). The LS mean (95% CI) treatment difference for MADRS total score also significantly favored LDX (-1.9 [-3.7, 0.0] P=0.0465). TEAE rates were 73.6% with placebo and 78.9% with LDX; serious TEAE rates were 4.2% and 2.8%. In this trial, LDX augmentation significantly improved executive dysfunction and depressive symptoms in participants with mild MDD. The safety profile of LDX was consistent with prior studies in adults with attention-deficit/hyperactivity disorder.Neuropsychopharmacology accepted article preview online, 6 December 2013. doi:10.1038/npp.2013.334.
PMID: 24309905 [PubMed – as supplied by publisher]
via http://www.ncbi.nlm.nih.gov/pubmed/24309905?dopt=Abstract
